{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:44:52Z","timestamp":1792633492765,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41571-020-0427-6","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T10:03:01Z","timestamp":1601028181000},"page":"71-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":246,"title":["CAR T cell therapies for patients with multiple myeloma"],"prefix":"10.1038","volume":"18","author":[{"given":"Lekha","family":"Mikkilineni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4362-9875","authenticated-orcid":false,"given":"James N.","family":"Kochenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"427_CR1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig, C., Knop, S. & Bornh\u00e4user, M. Multiple myeloma. Lancet 385, 2197\u20132208 (2015).","journal-title":"Lancet"},{"key":"427_CR2","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"427_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"427_CR4","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2019.37.15_suppl.8039","volume":"37","author":"B Nandakumar","year":"2019","unstructured":"Nandakumar, B. et al. Continued improvement in survival in multiple myeloma (MM) including high-risk patients. J. Clin. Oncol. 37, 8039\u20138039 (2019).","journal-title":"J. Clin. Oncol."},{"key":"427_CR5","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).","journal-title":"Nat. Commun."},{"key":"427_CR6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","volume":"111","author":"Y Furukawa","year":"2020","unstructured":"Furukawa, Y. & Kikuchi, J. Molecular basis of clonal evolution in multiple myeloma. Int. J. Hematol. 111, 496\u2013511 (2020).","journal-title":"Int. J. Hematol."},{"key":"427_CR7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar, S. K. & Rajkumar, S. V. The multiple myelomas \u2014 current concepts in cytogenetic classification and therapy. Nat. Rev. Clin. Oncol. 15, 409\u2013421 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"427_CR8","doi-asserted-by":"crossref","first-page":"100616","DOI":"10.1016\/j.blre.2019.100616","volume":"39","author":"C Durer","year":"2020","unstructured":"Durer, C. et al. Treatment of relapsed multiple myeloma: evidence-based recommendations. Blood Rev. 39, 100616 (2020).","journal-title":"Blood Rev."},{"key":"427_CR9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach, J. et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30, 1005\u20131017 (2016).","journal-title":"Leukemia"},{"key":"427_CR10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer, J. N. & Rosenberg, S. A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10, 267\u2013276 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"427_CR11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R. & Riviere, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388\u2013398 (2013).","journal-title":"Cancer Discov."},{"key":"427_CR12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., RiviSre, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"427_CR13","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700 (2016).","journal-title":"Blood"},{"key":"427_CR14","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267\u20132280 (2018).","journal-title":"J. Clin. Oncol."},{"key":"427_CR15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803\u20131813 (2017).","journal-title":"J. Clin. Oncol."},{"key":"427_CR16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31\u201346 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"427_CR17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"427_CR18","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"427_CR19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92\u2013101 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"427_CR20","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang, X. & Rivi\u00e8re, I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolytics 3, 16015 (2016).","journal-title":"Mol. Ther. Oncolytics"},{"key":"427_CR21","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"427_CR22","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood.V128.22.2167.2167","volume":"128","author":"BE Barnett","year":"2016","unstructured":"Barnett, B. E. et al. piggyBacTM-produced CAR-T cells exhibit stem-cell memory phenotype [abstract]. Blood 128, 2167 (2016).","journal-title":"Blood"},{"key":"427_CR23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOH.0000000000000181","volume":"22","author":"Y Yang","year":"2015","unstructured":"Yang, Y., Jacoby, E. & Fry, T. J. Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr. Opin. Hematol. 22, 509\u2013515 (2015).","journal-title":"Curr. Opin. Hematol."},{"key":"427_CR24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava, S. & Riddell, S. R. Engineering CAR-T cells: design concepts. Trends Immunol. 36, 494\u2013502 (2015).","journal-title":"Trends Immunol."},{"key":"427_CR25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"427_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","volume":"26","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C. & Restifo, N. P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26, 111\u2013117 (2005).","journal-title":"Trends Immunol."},{"key":"427_CR27","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907\u2013912 (2005).","journal-title":"J. Exp. Med."},{"key":"427_CR28","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Invest."},{"key":"427_CR29","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc. Natl Acad. Sci. USA 116, 9543\u20139551 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"Suppl. 1","key":"427_CR30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"B-Y Wang","year":"2019","unstructured":"Wang, B.-Y. et al. Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract]. Blood 134 (Suppl. 1), 579 (2019).","journal-title":"Blood"},{"key":"427_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao, W. H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11, 141 (2018).","journal-title":"J. Hematol. Oncol."},{"issue":"Suppl. 1","key":"427_CR32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","volume":"132","author":"S Mailankody","year":"2018","unstructured":"Mailankody, S. et al. Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial [abstract]. Blood 132 (Suppl. 1), 959 (2018).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR33","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2019-131515","volume":"134","author":"AL Garfall","year":"2019","unstructured":"Garfall, A. L. et al. Combination anti-Bcma and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma [abstract]. Blood 134 (Suppl. 1), 1863 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2019-126660","volume":"134","author":"JG Berdeja","year":"2019","unstructured":"Berdeja, J. G. et al. Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy [abstract]. Blood 134 (Suppl. 1), 927 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2019-121731","volume":"134","author":"D Madduri","year":"2019","unstructured":"Madduri, D. et al. Results from CARTITUDE-1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM) [abstract]. Blood 134 (Suppl. 1), 577 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2019-127309","volume":"134","author":"E Zudaire","year":"2019","unstructured":"Zudaire, E. et al. Translational analysis from CARTITUDE-1, an ongoing phase 1b\/2 study of JNJ-4528 BCMA-targeted CAR-T cell therapy in relapsed and\/or refractory multiple myeloma (R\/R MM), indicates preferential expansion of CD8+ T cell central memory cell subset [abstract]. Blood 134 (Suppl. 1), 928 (2019).","journal-title":"Blood"},{"key":"427_CR37","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2217\/rme-2020-0009","volume":"15","author":"D Ilic","year":"2020","unstructured":"Ilic, D. & Liovic, M. Industry updates from the field of stem cell research and regenerative medicine in December 2019. Regen. Med. 15, 1499\u20131507 (2020).","journal-title":"Regen. Med."},{"issue":"Suppl. 1","key":"427_CR38","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","volume":"132","author":"D Green","year":"2018","unstructured":"Green, D. et al. Fully human BCMA targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma [abstract]. Blood 132 (Suppl. 1), 1011 (2018).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR39","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2019-129088","volume":"134","author":"L Mikkilineni","year":"2019","unstructured":"Mikkilineni, L. et al. T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma [abstract]. Blood 134 (Suppl. 1), 3230 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2019-129405","volume":"134","author":"AJ Cowan","year":"2019","unstructured":"Cowan, A. J. et al. Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma Surface expression in patients with relapsed or refractory multiple myeloma [abstract]. Blood 134 (Suppl. 1), 204 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR41","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2019-129582","volume":"134","author":"D Green","year":"2019","unstructured":"Green, D. et al. Response to BCMA CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase [abstract]. Blood 134 (Suppl. 1), 1856 (2019).","journal-title":"Blood"},{"key":"427_CR42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"427_CR43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"427_CR44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter, D., Frey, N., Wood, P. A., Weng, Y. & Grupp, S. A. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J. Hematol. Oncol. 11, 35 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"427_CR45","first-page":"188","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"427_CR46","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"427_CR47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 34, 45\u201355 (2019).","journal-title":"Blood Rev."},{"key":"427_CR48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"427_CR49","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.bbmt.2018.12.311","volume":"25","author":"A Schaefer","year":"2019","unstructured":"Schaefer, A. et al. Cytopenias after chimeric antigen receptor T-cells (CAR-T) infusion; patterns and outcomes. Biol. Blood Marrow Transplant. 25, S171 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"427_CR50","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"427_CR51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","volume":"41","author":"H Shalabi","year":"2018","unstructured":"Shalabi, H. et al. Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. J. Immunother. 41, 350\u2013358 (2018).","journal-title":"J. Immunother."},{"key":"427_CR52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett, T. & Brown, M. P. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front.Pharmacol. 5, 235 (2014).","journal-title":"Front.Pharmacol."},{"key":"427_CR53","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","volume":"5","author":"BS Jones","year":"2014","unstructured":"Jones, B. S., Lamb, L. S., Goldman, F. & Di Stasi, A. Improving the safety of cell therapy products by suicide gene transfer. Front.Pharmacol. 5, 254 (2014).","journal-title":"Front.Pharmacol."},{"issue":"21","key":"427_CR54","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood.V120.21.949.949","volume":"120","author":"M Casucci","year":"2012","unstructured":"Casucci, M. et al. Co-expression of a suicide gene in CAR-redirected T cells enables the safe targeting of CD44v6 for leukemia and myeloma eradication [abstract]. Blood 120 (21), 949 (2012).","journal-title":"Blood"},{"key":"427_CR55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2018.00507","volume":"9","author":"M Casucci","year":"2018","unstructured":"Casucci, M. et al. Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene. Front. Immunol. 9, 507 (2018).","journal-title":"Front. Immunol."},{"key":"427_CR56","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"427_CR57","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20\u2013e22 (2006).","journal-title":"J. Clin. Oncol."},{"key":"427_CR58","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"427_CR59","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","volume":"11","author":"Y La\u00e2bi","year":"1992","unstructured":"La\u00e2bi, Y. et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J. 11, 3897\u20133904 (1992).","journal-title":"EMBO J."},{"key":"427_CR60","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689\u2013694 (2004).","journal-title":"Blood"},{"key":"427_CR61","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048\u20132060 (2013).","journal-title":"Clin. Cancer Res."},{"key":"427_CR62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O'Connor","year":"2004","unstructured":"O\u2019Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"427_CR63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","volume":"173","author":"LG Ng","year":"2004","unstructured":"Ng, L. G. et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 173, 807\u2013817 (2004).","journal-title":"J. Immunol."},{"key":"427_CR64","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25, 2245\u20132253 (2017).","journal-title":"Mol. Ther."},{"key":"427_CR65","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat. Med. 26, 270\u2013280 (2020).","journal-title":"Nat. Med."},{"key":"427_CR66","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman, K. M. et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum. Gene Ther. 29, 585\u2013601 (2018).","journal-title":"Hum. Gene Ther."},{"key":"427_CR67","unstructured":"Bristol Myers Squibb. Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibb-and-bluebird-bio-announce-positive-top-li (2019)."},{"issue":"Suppl. 1","key":"427_CR68","first-page":"1813","volume":"130","author":"K Harrington","year":"2017","unstructured":"Harrington, K. et al. Development of JCARH125: optimization of a fully human anti-BCMA CAR for use in the treatment of multiple myeloma [abstract]. Blood 130 (Suppl. 1), 1813 (2017).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","volume":"132","author":"S Mailankody","year":"2018","unstructured":"Mailankody, S. et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE) [abstract]. Blood 132 (Suppl. 1), 957 (2018).","journal-title":"Blood"},{"key":"427_CR70","doi-asserted-by":"crossref","first-page":"101141","DOI":"10.1016\/j.beha.2020.101141","volume":"33","author":"UA Shah","year":"2020","unstructured":"Shah, U. A. & Mailankody, S. CAR T and CAR NK cells in multiple myeloma: expanding the targets. Best Pract. Res. Clin. Haematol. 33, 101141 (2020).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"427_CR71","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/PPO.0000000000000379","volume":"25","author":"UA Shah","year":"2019","unstructured":"Shah, U. A. & Smith, E. L. Multiple myeloma, targeting B-cell maturation antigen with chimeric antigen receptor T-cells. Cancer J. 25, 208\u2013216 (2019).","journal-title":"Cancer J."},{"issue":"Suppl. 1","key":"427_CR72","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2018-99-110548","volume":"132","author":"W-H Zhao","year":"2018","unstructured":"Zhao, W.-H. et al. Updated analysis of a phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B-cell maturation antigen, in patients with relapsed\/refractory multiple myeloma [abstract]. Blood 132 (Suppl. 1), 955 (2018).","journal-title":"Blood"},{"key":"427_CR73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"H Du","year":"2019","unstructured":"Du, H. et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell 35, 221\u2013237.e8 (2019).","journal-title":"Cancer Cell"},{"key":"427_CR74","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam, N. et al. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat. Commun. 11, 283 (2020).","journal-title":"Nat. Commun."},{"issue":"Suppl. 1","key":"427_CR75","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood.V130.Suppl_1.742.742","volume":"130","author":"EL Smith","year":"2017","unstructured":"Smith, E. L. et al. Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T cell vector leads to a high objective response rate in patients with advanced MM [abstract]. Blood 130 (Suppl. 1), 742 (2017).","journal-title":"Blood"},{"key":"427_CR76","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl Med. 8, 355ra116 (2016).","journal-title":"Sci. Transl Med."},{"issue":"22","key":"427_CR77","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1182\/blood.V128.22.4557.4557","volume":"128","author":"BE Barnett","year":"2016","unstructured":"Barnett, B. E. et al. Development of novel non-immunoglobulin Centyrin-based Cars (CARTyrins) targeting human BCMA [abstract]. Blood 128 (22), 4557 (2016).","journal-title":"Blood"},{"issue":"22","key":"427_CR78","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.V128.22.2127.2127","volume":"128","author":"DL Hermanson","year":"2016","unstructured":"Hermanson, D. L. et al. A novel BCMA-specific, Centyrin-based CAR-T product for the treatment of multiple myeloma [abstract]. Blood 128 (22), 2127 (2016).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR79","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","volume":"132","author":"T Gregory","year":"2018","unstructured":"Gregory, T. et al. Efficacy and safety of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) [abstract]. Blood 132 (Suppl. 1), 1012 (2018).","journal-title":"Blood"},{"key":"427_CR80","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont, M. J. et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134, 1585\u20131597 (2019).","journal-title":"Blood"},{"key":"427_CR81","doi-asserted-by":"crossref","unstructured":"Dammacco, F., Leone, P., Silvestris, F., Racanelli, V. & Vacca, A. in Oncogenomics (eds Franco Dammacco & Franco Silvestris) 121\u2013137 (Academic Press, 2019).","DOI":"10.1016\/B978-0-12-811785-9.00009-0"},{"key":"427_CR82","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00109-009-0531-7","volume":"87","author":"SK Brennan","year":"2009","unstructured":"Brennan, S. K. & Matsui, W. Cancer stem cells: controversies in multiple myeloma. J. Mol. Med. 87, 1079 (2009).","journal-title":"J. Mol. Med."},{"key":"427_CR83","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.12563","volume":"163","author":"R Hajek","year":"2013","unstructured":"Hajek, R., Okubote, S. A. & Svachova, H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br. J. Haematol. 163, 551\u2013564 (2013).","journal-title":"Br. J. Haematol."},{"key":"427_CR84","doi-asserted-by":"crossref","first-page":"35466","DOI":"10.18632\/oncotarget.8154","volume":"7","author":"M Gao","year":"2016","unstructured":"Gao, M., Kong, Y., Yang, G., Gao, L. & Shi, J. Multiple myeloma cancer stem cells. Oncotarget 7, 35466\u201335477 (2016).","journal-title":"Oncotarget"},{"issue":"22","key":"427_CR85","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood.V128.22.974.974","volume":"128","author":"A Garfall","year":"2016","unstructured":"Garfall, A. et al. Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma [abstract]. Blood 128 (22), 974 (2016).","journal-title":"Blood"},{"key":"427_CR86","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall, A. L. et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373, 1040\u20131047 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"427_CR87","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2019-131056","volume":"134","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. A BCMA and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma [abstract]. Blood 134 (Suppl. 1), 3147 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR88","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood-2019-131546","volume":"134","author":"X Shi","year":"2019","unstructured":"Shi, X. et al. Combined infusion of anti-CD19 and anti-BCMA CART cells after early or later transplantation in the front line was superior to salvage therapy for high risk MM [abstract]. Blood 134 (Suppl. 1), 1949 (2019).","journal-title":"Blood"},{"key":"427_CR89","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","volume":"3","author":"AL Garfall","year":"2018","unstructured":"Garfall, A. L. et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3, e120505 (2018).","journal-title":"JCI Insight"},{"key":"427_CR90","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","volume":"12","author":"S Vairy","year":"2018","unstructured":"Vairy, S., Garcia, J. L., Teira, P. & Bittencourt, H. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des. Devel. Ther. 12, 3885\u20133898 (2018).","journal-title":"Drug Des. Devel. Ther."},{"key":"427_CR91","doi-asserted-by":"crossref","first-page":"E521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"ZL Yan","year":"2019","unstructured":"Yan, Z. L. et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 6, E521\u2013E529 (2019).","journal-title":"Lancet Haematol."},{"key":"427_CR92","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi, E. D. et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14, 2775\u20132784 (2008).","journal-title":"Clin. Cancer Res."},{"key":"427_CR93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coi.2015.11.003","volume":"38","author":"N Wu","year":"2016","unstructured":"Wu, N. & Veillette, A. SLAM family receptors in normal immunity and immune pathologies. Curr. Opin. Immunol. 38, 45\u201351 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"427_CR94","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","volume":"88","author":"A Veillette","year":"2013","unstructured":"Veillette, A. & Guo, H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit. Rev. Oncol. Hematol. 88, 168\u2013177 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"427_CR95","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","volume":"130","author":"T Gogishvili","year":"2017","unstructured":"Gogishvili, T. et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood 130, 2838\u20132847 (2017).","journal-title":"Blood"},{"key":"427_CR96","doi-asserted-by":"crossref","unstructured":"Calpe, S. et al. in Advances in Immunology Vol. 97 (ed. Alt, F. W.) 177\u2013250 (Academic Press, 2008).","DOI":"10.1016\/S0065-2776(08)00004-7"},{"key":"427_CR97","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s002510000274","volume":"52","author":"KS Boles","year":"2001","unstructured":"Boles, K. S. & Mathew, P. A. Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics 52, 302\u2013307 (2001).","journal-title":"Immunogenetics"},{"key":"427_CR98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1744666X.2016.1209112","volume":"13","author":"JS Boudreault","year":"2017","unstructured":"Boudreault, J. S., Touzeau, C. & Moreau, P. The role of SLAMF7 in multiple myeloma: impact on therapy. Expert. Rev. Clin. Immunol. 13, 67\u201375 (2017).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"427_CR99","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14712598.2016.1221920","volume":"16","author":"S Lonial","year":"2016","unstructured":"Lonial, S. et al. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert. Opin. Biol. Ther. 16, 1291\u20131301 (2016).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"427_CR100","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","volume":"20","author":"J Chu","year":"2014","unstructured":"Chu, J. et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin. Cancer Res. 20, 3989\u20134000 (2014).","journal-title":"Clin. Cancer Res."},{"key":"427_CR101","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"key":"427_CR102","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl Med. 11, eaau7746 (2019).","journal-title":"Sci. Transl Med."},{"issue":"Suppl. 1","key":"427_CR103","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2019-126145","volume":"134","author":"C Fernandez de Larrea","year":"2019","unstructured":"Fernandez de Larrea, C. et al. Optimal dual-targeted CAR construct simultaneously targeting BCMA and GPRC5D prevents BCMA-escape driven relapse in multiple myeloma [abstract]. Blood 134 (Suppl. 1), 136 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR104","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2018-99-117964","volume":"132","author":"X Shi","year":"2018","unstructured":"Shi, X. et al. Tandom autologous transplantation and combined infusion of CD19 and BCMA-specific chimeric antigen receptor T cells for high risk MM: initial safety and efficacy report from a clinical pilot study [abstract]. Blood 132 (Suppl. 1), 1009 (2018).","journal-title":"Blood"},{"key":"427_CR105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.15252\/emmm.201607265","volume":"9","author":"Y Ran","year":"2017","unstructured":"Ran, Y. et al. \u03b3-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol. Med. 9, 950\u2013966 (2017).","journal-title":"EMBO Mol. Med."},{"key":"427_CR106","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","volume":"26","author":"EL Smith","year":"2018","unstructured":"Smith, E. L. et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol. Ther. 26, 1447\u20131456 (2018).","journal-title":"Mol. Ther."},{"key":"427_CR107","doi-asserted-by":"crossref","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).","journal-title":"Sci. Signal."},{"key":"427_CR108","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza, L. et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol. Ther. 25, 2452\u20132465 (2017).","journal-title":"Mol. Ther."},{"key":"427_CR109","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove, R., George, P., Dasyam, N. & McLellan, A. D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl Immunol. 8, e1049 (2019).","journal-title":"Clin. Transl Immunol."},{"key":"427_CR110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"427_CR111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2015.12.001","volume":"28","author":"C Geldres","year":"2016","unstructured":"Geldres, C., Savoldo, B. & Dotti, G. Chimeric antigen receptor-redirected T cells return to the bench. Semin. Immunol. 28, 3\u20139 (2016).","journal-title":"Semin. Immunol."},{"key":"427_CR112","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947\u2013953 (2019).","journal-title":"Nat. Med."},{"key":"427_CR113","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1074-7613(00)80564-6","volume":"8","author":"X Zhang","year":"1998","unstructured":"Zhang, X., Sun, S., Hwang, I., Tough, D. F. & Sprent, J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8, 591\u2013599 (1998).","journal-title":"Immunity"},{"key":"427_CR114","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"427_CR115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128, 519\u2013528 (2016).","journal-title":"Blood"},{"key":"427_CR116","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"427_CR117","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki, N., Jain, A. & Campana, D. NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200\u2013218 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"427_CR118","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41409-019-0601-6","volume":"54","author":"K Rezvani","year":"2019","unstructured":"Rezvani, K. Adoptive cell therapy using engineered natural killer cells. Bone Marrow Transplant. 54, 785\u2013788 (2019).","journal-title":"Bone Marrow Transplant."},{"key":"427_CR119","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"427_CR120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark, C. et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100, 107\u2013113 (2015).","journal-title":"Haematologica"},{"key":"427_CR121","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","volume":"171","author":"BW Teh","year":"2015","unstructured":"Teh, B. W. et al. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br. J. Haematol. 171, 100\u2013108 (2015).","journal-title":"Br. J. Haematol."},{"issue":"Suppl. 1","key":"427_CR122","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood-2019-131170","volume":"134","author":"L Mikkilineni","year":"2019","unstructured":"Mikkilineni, L. et al. Infectious complications associated with CAR T-cell therapy [abstract]. Blood 134 (Suppl. 1), 4449 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR123","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1182\/blood-2019-127452","volume":"134","author":"TIS Syed","year":"2019","unstructured":"Syed, T. I. S. et al. Infections associated with CAR T therapy for treatment of hematological malignancies [abstract]. Blood 134 (Suppl. 1), 4442 (2019).","journal-title":"Blood"},{"key":"427_CR124","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","volume":"7","author":"H Luo","year":"2019","unstructured":"Luo, H. et al. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J. Immunother. Cancer 7, 271 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"427_CR125","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood.V120.21.1797.1797","volume":"120","author":"JH Park","year":"2012","unstructured":"Park, J. H. et al. Impact of the conditioning chemotherapy on outcomes in adoptive T cell therapy: results from a phase I clinical trial of autologous CD19-targeted T cells for patients with relapsed CLL [abstract]. Blood 120, 1797 (2012).","journal-title":"Blood"},{"key":"427_CR126","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","volume":"24","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin. Cancer Res. 24, 106\u2013119 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 1","key":"427_CR127","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2019-122396","volume":"134","author":"M Wang","year":"2019","unstructured":"Wang, M. et al. Response to anti-BCMA CAR T cell therapy correlates with T cell exhaustion and activation status in T cells at baseline in myeloma [abstract]. Blood 134 (Suppl. 1), 1909 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR128","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2019-121715","volume":"134","author":"S Sidana","year":"2019","unstructured":"Sidana, S. et al. Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. stem cell transplant: longitudinal patient reported adverse events, cognition and quality of life [abstract]. Blood 134 (Suppl. 1), 794 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR129","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2019-129562","volume":"134","author":"CL Costello","year":"2019","unstructured":"Costello, C. L. et al. Phase 2 study of the response and safety of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) [abstract]. Blood 134 (Suppl. 1), 3184 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR130","first-page":"3068","volume":"130","author":"R Mathur","year":"2017","unstructured":"Mathur, R. et al. B-cell maturation antigen (BCMA)-specific, CentyrinTM-based, PiggyBacTM-transposed CAR-T memory stem cells are effective against p53-\/- and patient-derived multiple myeloma tumors [abstract]. Blood 130 (Suppl. 1), 3068 (2017).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR131","first-page":"505","volume":"130","author":"AD Cohen","year":"2017","unstructured":"Cohen, A. D. et al. Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM) [abstract]. Blood 130 (Suppl. 1), 505 (2017).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR132","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood-2019-128468","volume":"134","author":"C Li","year":"2019","unstructured":"Li, C. et al. Efficacy and safety of fully human BCMA targeting CAR T cell therapy in relapsed\/refractory multiple myeloma [abstract]. Blood 134 (Suppl. 1), 929 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR133","first-page":"3154","volume":"134","author":"W Fu Sr","year":"2019","unstructured":"Fu, W. Sr et al. Efficacy and safety of CAR-T therapy with safety switch targeting BCMA for patients with relapsed\/refractory multiple myeloma in a phase 1 clinical study [abstract]. Blood 134 (Suppl. 1), 3154 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR134","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2018-99-112786","volume":"132","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Durable remission achieved from BCMA-directed car-T therapy against relapsed or refractory multiple myeloma [abstract]. Blood 132 (Suppl. 1), 956 (2018).","journal-title":"Blood"},{"issue":"Suppl. 15","key":"427_CR135","doi-asserted-by":"crossref","first-page":"8020","DOI":"10.1200\/JCO.2018.36.15_suppl.8020","volume":"36","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed\/refractory multiple myeloma [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 8020 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"427_CR136","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","volume":"132","author":"C Li","year":"2018","unstructured":"Li, C. et al. T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies [abstract]. Blood 132 (Suppl. 1), 1013 (2018).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR137","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/blood-2019-126104","volume":"134","author":"J Jie","year":"2019","unstructured":"Jie, J. et al. Phase 1 trial of the safety and efficacy of fully human anti-BCMA CAR T cells in relapsed\/refractory multiple myeloma [abstract]. Blood 134 (Suppl. 1), 4435 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR138","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2019-126689","volume":"134","author":"R Popat","year":"2019","unstructured":"Popat, R. et al. Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM) [abstract]. Blood 134 (Suppl. 1), 3112 (2019).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"427_CR139","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood-2019-129740","volume":"134","author":"L Yan","year":"2019","unstructured":"Yan, L. et al. Sequential CD19- and BCMA-specific chimeric antigen receptor T cell treatment for RRMM: report from a single center study [abstract]. Blood 134 (Suppl. 1), 578 (2019).","journal-title":"Blood"},{"key":"427_CR140","first-page":"1723","volume":"49","author":"C Li","year":"2019","unstructured":"Li, C. et al. Improved efficacy and safety of a dual-target CAR-T cell therapy targeting BCMA and CD38 for relapsed\/refractory multiple myeloma from a phase I study. Eur. J. Immunol. 49, 1723\u20131724 (2019).","journal-title":"Eur. J. Immunol."},{"issue":"Suppl. 1","key":"427_CR141","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/blood-2019-130340","volume":"134","author":"C Li","year":"2019","unstructured":"Li, C. et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 for relapsed\/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial [abstract]. Blood 134 (Suppl. 1), 930 (2019).","journal-title":"Blood"},{"key":"427_CR142","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","volume":"126","author":"CA Ramos","year":"2016","unstructured":"Ramos, C. A. et al. Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains. J. Clin. Invest. 126, 2588\u20132596 (2016).","journal-title":"J. Clin. Invest."},{"key":"427_CR143","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","volume":"71","author":"DA Salem","year":"2018","unstructured":"Salem, D. A. et al. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma. Leuk. Res. 71, 106\u2013111 (2018).","journal-title":"Leuk. Res."},{"key":"427_CR144","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister, S. H. et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol. Res. 7, 100\u2013112 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"427_CR145","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","volume":"22","author":"Y Laabi","year":"1994","unstructured":"Laabi, Y. et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 22, 1147\u20131154 (1994).","journal-title":"Nucleic Acids Res."},{"key":"427_CR146","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1615\/CritRevImmunol.v32.i4.10","volume":"32","author":"CM Coquery","year":"2012","unstructured":"Coquery, C. M. & Erickson, L. D. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit. Rev. Immunol. 32, 287\u2013305 (2012).","journal-title":"Crit. Rev. Immunol."},{"key":"427_CR147","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"Y-T Tai","year":"2015","unstructured":"Tai, Y.-T. & Anderson, K. C. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 7, 1187\u20131199 (2015).","journal-title":"Immunotherapy"},{"key":"427_CR148","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14737159.2018.1448269","volume":"18","author":"E Sanchez","year":"2018","unstructured":"Sanchez, E. et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev. Mol. Diagn. 18, 319\u2013329 (2018).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"427_CR149","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","volume":"21","author":"S Xu","year":"2001","unstructured":"Xu, S. & Lam, K. P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell Biol. 21, 4067\u20134074 (2001).","journal-title":"Mol. Cell Biol."},{"key":"427_CR150","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","volume":"112","author":"DT Avery","year":"2003","unstructured":"Avery, D. T. et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest 112, 286\u2013297 (2003).","journal-title":"J. Clin. Invest"},{"key":"427_CR151","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.4049\/jimmunol.178.9.5612","volume":"178","author":"JR Darce","year":"2007","unstructured":"Darce, J. R., Arendt, B. K., Chang, S. K. & Jelinek, D. F. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. J. Immunol. 178, 5612\u20135622 (2007).","journal-title":"J. Immunol."},{"key":"427_CR152","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","volume":"179","author":"JR Darce","year":"2007","unstructured":"Darce, J. R., Arendt, B. K., Wu, X. & Jelinek, D. F. Regulated expression of BAFF-binding receptors during human B cell differentiation. J. Immunol. 179, 7276\u20137286 (2007).","journal-title":"J. Immunol."},{"key":"427_CR153","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985\u20131005 (2020).","journal-title":"Leukemia"},{"key":"427_CR154","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"J Moreaux","year":"2004","unstructured":"Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148\u20133157 (2004).","journal-title":"Blood"},{"key":"427_CR155","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"S-F Cho","year":"2018","unstructured":"Cho, S.-F., Anderson, K. C., Tai, Y.-T. & Targeting, B. Cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front. Immunol. 9, 1821 (2018).","journal-title":"Front. Immunol."},{"key":"427_CR156","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent, S. A. et al. \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 6, 7333 (2015).","journal-title":"Nat. Commun."},{"key":"427_CR157","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911\u2013922 (2016).","journal-title":"Br. J. Haematol."},{"issue":"21","key":"427_CR158","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1182\/blood.V122.21.4447.4447","volume":"122","author":"KL Yong","year":"2013","unstructured":"Yong, K. L. et al. Evaluation of BCMA as a therapeutic target in multiple myeloma using an antibody-drug conjugate [abstract]. Blood 122 (21), 4447 (2013).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0427-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0427-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0427-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T19:42:01Z","timestamp":1632512521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0427-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":158,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1038\/s41571-020-0427-6","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"3 August 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}